Company Name Allena Pharmaceuticals
Mailing Address One Newton Executive Park Newton, MA 02462 USA
Company Description Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.
Proceeds Purposes Allena intends to use the proceeds from the financing to advance its lead product candidate, ALLN-177 for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones, into Phase 3 clinical trials. The proceeds will also be used to explore additional indications for ALLN-177, including oxalate nephropathy and primary hyperoxaluria, and to develop new product candidates utilizing Allena’s non-systemic oral protein therapeutic platform.
Venture Investor Partner Fund Management
Venture Investor Fidelity Management & Research Company